On September 22, 2015, we received approval from the U.S. Food and Drug Administration (FDA) for LONSURF® (trifluridine and tipiracil).
To learn more about LONSURF, please visit the links below:
OUR PRODUCTS
Taiho Oncology, Inc. is continually researching and developing innovative anti-cancer therapies, as part of our ongoing efforts to improve human health and contribute to a society enriched by smiles. Here are some of the products we are proud to offer.
WHAT WE HAVE TO OFFER
On July 7, 2020, we received approval from the U.S. Food and Drug Administration (FDA) for INQOVI® (decitabine and cedazuridine).
To learn more about INQOVI, please visit the links below:
On September 30, 2022, we received approval from the U.S. Food and Drug Administration (FDA) for LYTGOBI® (futibatinib).
To learn more about LYTGOBI, please visit the links below:
Learn more about Taiho Oncology Patient Support™
Find out about the patient access and support services we offer.